Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.

A district court judge vanquished Janssen Biotech Inc.'s hopes of delaying the launch of Celltrion Inc./Pfizer Inc.'s Remicade (infliximab) biosimilar until the composition patent expires in September 2018.

Massachusetts District Court Judge Mark Wolf issued an oral ruling Aug. 17 that the patent, No. 6,284,471, which covers the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics